{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-023380","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2023-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.748089+00:00","generated_at":"2026-06-14T18:26:27.759031+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Revelation Biosciences reports Q1 net income of $6.2M; cash $17.7M; IND work ongoing","bullets":["Q1 2023 net income $6.2M ($2.79 basic EPS) vs net loss $6.6M in Q1 2022; driven by $7.7M warrant liability gain.","Cash and equivalents $17.7M at March 31, 2023, up from $5.3M at Dec 31, 2022; net cash used in ops $1.6M.","Management expects existing cash to fund operations through June 2024.","IND and clinical enabling studies for REVTx-300 and REVTx-100 underway; Phase 1 start targeted Q4 2023.","Decreased clinical study expenses due to completion of prior Phase 2b and Phase 1b studies."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-023380","json":"https://secwatch.observer/filing/0000950170-23-023380.json","markdown":"https://secwatch.observer/filing/0000950170-23-023380.md","text":"https://secwatch.observer/filing/0000950170-23-023380.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023023380/0000950170-23-023380-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023023380/revb-20230522.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T18:26:27.759031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dbdee276f53b244bb760f37f1a56ac525e8aa79b","claim":"REVELATION BIOSCIENCES, INC. reported three months ended March 31, 2023 results: net income $6.2 million, EPS $2.79 basic earnings per share and $1.96 diluted earnings per share.","evidence_excerpt":"Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2023 and Recent Corporate Progress","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810560/000095017023023380/0000950170-23-023380-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Net income","value":"$6.2 million"},{"label":"EPS","value":"$2.79 basic earnings per share and $1.96 diluted earnings per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}